Compare Cytokinetics Inc (CYTK) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Mercadolibre Inc — how do they compare? Cytokinetics Inc trades at $62.2 (market cap $8.62B), while Mercadolibre Inc trades at $1,867.32 (market cap $94.13B). The key difference: Mercadolibre Inc is far larger — about 10.9× Cytokinetics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Mercadolibre Inc for 117 Days on average.
| CYTK | MELI | |
|---|---|---|
Market Cap | $8.62B | $94.13B |
Volume | 2,594,626 | 273,781 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $2.36K |
52-Week Low | $54.76 | $1.55K |
Typical Hold Time | 19 Days | 117 Days |
Enterprise Value | $8.72B | $101.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
MercadoLibre (MELI) trades at $1,868.01, down 0.25% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin compressed to 6.91%. Recent news highlights expansion in Brazil's delivery and pharmacy segments, while analyst consensus remains strongly bullish with a $2,170 price target.
MELI's integrated e-commerce and fintech ecosystem in Latin America presents significant growth potential, supported by expanding credit portfolios and advertising revenue. Key risks include macroeconomic pressures in Argentina and margin compression from increased investment. With 73% analyst buy ratings and institutional accumulation, the stock offers growth exposure but requires monitoring of profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
